This June, at the European Hematology Association (EHA) annual meeting, we will share 17 data presentations describing new findings and progress in our oncology portfolio and pipeline. The presentations will underscore our commitment to maximising patient survival and improving outcomes by developing transformative medicines for people with blood cancers.
Our research into new therapeutic approaches that target key pathways and maximise anti-tumour activity drives our strong oncology pipeline and clinical trial programme, now with 12 assets in development.
Our therapies utilise tumour cell targeting to expand options for patients in an effort to improve outcomes and quality of life for people with cancer. We are exploring new treatment approaches for our currently marketed medicines, both used alone and in combination, that have the potential to address some of the biggest challenges in oncology.
If you are a healthcare professional, you can learn more about our marketed products by selecting your market and the specific GSKPro website on our worldwide directory.
Patient stories
Targeting a better future for multiple myeloma patients
GSK is driving progress for the multiple myeloma community by identifying and accelerating innovative solutions. Now in its second year, GSK’s Target the Future Think Tank Challenge awards funding to an individual or group with the most innovative idea to address the unmet needs of people with multiple myeloma. The inaugural grant recipient in 2022 – HealthTree Foundation – is utilising Target the Future funding and GSK resources to improve access, education, and support for underserved communities and minority patients. This year, we’re targeting disparities presently affecting multiple myeloma care and look forward to supporting ideas to address unmet needs.
We are currently accepting grant applications for the 2023 Think Tank Challenge . Find out more about your eligibility and submit your application at our Target the Future site.
Go behind the science
Discover how we’re uniting technology, science, and talent to get ahead of cancer and advance a new generation of cancer therapies.
